CASE CCC IN THE NEWS
Stem Cells to Repair Broken Chromosomes
WKLSTV.com - Nov 7, 2014
Case Western scientist and Case Comprehensive Cancer Center member Anthony Wynshaw-Boris is studying how to repair damaged chromosomes with the help of a recent discovery. He's taking skin cells and reprogramming them to work like embryonic stem cells, which can grow into different cell types. "You're taking adult or a child's skin cells. You're not causing any loss of an embryo, and you're taking those skin cells to make a stem cell, " Anthony Wynshaw-Boris, MD, PhD of Case Western Reserve University, School of Medicine told Ivanhoe.
Rate of Colorectal Cancer in Young Adults in the U.S. is Rising, Study Shows
The Plain Dealer - Nov 6, 2014
The incidence of colorectal cancer in people under 50 - the age at which screening is recommended - has gone up and will continue to rise, according to findings in a study published online in the journal JAMA Surgery. The biggest increase is in patients under age 35, the study said...Dr. Gregory Cooper,a gastroenterologist at University Hospitals Case Medical Center and co-leader of the Case CCC Cancer Prevention, Control & Population Research Program, agrees, adding that he doesn't think young adults would embrace the invasive test. "We have a hard enough time getting 50-year-olds to come in," he said.
Ramucirumab/Paclitaxel Combo Approved for Gastric Cancer
Medscape - Nov 6, 2014
The new antiangiogenesis agent ramucirumab (Cyramza, Lilly) has been granted an indication extension by the US Food and Drug Administration (FDA)...The FDA approval for use of the drug in combination with paclitaxel is based on the results from the phase 3 RAINBOW trial, which compared the combination with paclitaxel alone. The results showed a significant improvement in overall survival (9.6 vs 7.4 months; hazard ratio [HR], 0.87; P = .0169), as reported earlier this year at the 2014 Gastrointestinal Cancers Symposium. The results were highlighted at a press briefing, at which Smitha S. Krishnamurthi, MD, Associate Professor of Medicine and member of the Case Comprehensive Cancer Center at Case Western Reserve University in Cleveland, Ohio, said, "This is the only study to date to demonstrate a 2-month improvement in survival in this setting, and with a relatively high 28% response rate for the combination therapy."
Platelet Mimics Offer New Hope for Treating Bleeding Disorders
Genetic Engineering & Biotechnology News - Nov 6, 2014
Scientists at Case Western Reserve University and the University of California, Santa Barbara report the development of artificial platelet mimics that halted bleeding in mouse models 65% quicker than if nature was working on its own. The researchers said they integratively mimicked the shape, size, flexibility, and surface chemistry of real blood platelets on albumin-based particle platforms...Anirban Sen Gupta, PhD, an associate professor of biomedical engineering and member of the Case Comprehensive Cancer Center at Case Western Reserve, previously designed peptide-based surface chemistries that mimic the clot-relevant activities of real platelets. Building on this work, Dr. Sen Gupta now focuses on incorporating morphological and mechanical cues that are naturally present in platelets to further refine the design. "Morphological and mechanical factors influence the margination of natural platelets to the blood vessel wall, and only when they are near the wall can the critical clot-promoting chemical interactions take place," he said.
What Control do you Have Over Your End-of-life Decisions?
WKYC - Nov 3, 2014
Brittany Maynard, the 29-year-old terminal brain cancer patient, may have ended her life on Sunday, but she sparked debate over assisted suicide that may last months. Only five states allow assisted suicide: Montana, Vermont, Washington, Oregon and New Mexico. Maynard moved from California to Oregon to access the state's Death with Dignity Act. Assisted suicide is illegal in Ohio. "This is a fundamental ethical question," says Barbara Daly, PhD, Director of the Clinical Ethics Department at University Hospitals Case Medical Center, and Case Comprehensive Cancer Center member. "States that have gone the route of physician aid-in-dying have come down on the side that this is a fundamental human right, to decide the circumstances of your death."
MEMBER & RESEARCH HIGHLIGHTS
CPEN Excellence in Patient Education Award
Congratulations to the team of Regina Carlisle, RN, Chesley Cheatham, MED, MCHES, Melissa O'Grady, MLIS, and Paula Schultz, RN, CNRN from UH Seidman Cancer Center (SCC) Department of Patient and Public Education who received the 2014 Cancer Patient Education Network (CPEN) Excellence in Cancer Patient Education Award at the International Cancer Education Conference in Clearwater Florida, October 24. The award was presented for the team's work creating plain language titles and descriptions to aid the general public in navigating and understanding trials on the SCC Clinical Trials Website/App.
CCIPD/BME Graduate Student Wins Young Scientist Runners up at MICCAI 2014
Prateek Prasanna, a Biomedical Engineering PhD student, was awarded runner up for the young scientist award at Medical Image Computing and Computer Assisted Intervention (MICCAI), a leading medical imaging conference, for his oral presentation, Co-occurrence of Local Anisotropic Gradient Orientations (CoLlAGe) for tumor classification. The paper was jointly authored by Dr. Pallavi Tiwari, with Dr. Anant Madabhushi as a senior author. Prateek is mentored by Dr. Anant Madabhushi, Professor at Case Western Reserve's Department of Biomedical Engineering and Director of the Center for Computational Imaging and Personalized Diagnostics, and Dr. Pallavi Tiwari, Research Assistant Professor [BME/CCIPD]. Of all papers submitted to the MICCAI conference, (~1,000 papers), only 15 papers were nominated for the award.
AMERICAN ASSOCIATION FOR CANCER RESEARCH
AACR Annual Meeting 2015: Call for Clinical Trials Abstracts
The AACR Annual Meeting will be held April 18-22, 2015 in Philadelphia. AACR is encouraging attendees to submit clinical trials for presentation at the AACR Annual Meeting 2015 to facilitate the continued growth of the invaluable clinical content of this meeting. There will be at least 38 opportunities for the oral presentation of clinical trials at the Annual Meeting, including the presentation in the Opening Plenary Session of an outstanding clinical trial that holds promise for changing clinical practice and approaches. We also offer four marquee Clinical Trials Symposia which will feature tandem presentations of the trial data and the science informing the trial. Please keep in mind that there are also many poster sessions, including one focusing on highly informative "Trials in Progress."
Clinical trial abstracts that are available by the Wednesday, Dec. 3, 2014 deadline should be submitted to the appropriate Clinical Trial (CT) category. Late-breaking and placeholder abstracts should be submitted by Tuesday, Jan. 27, 2015. If a placeholder abstract is submitted, completed abstracts must be submitted no later than Friday, Feb. 27, 2015. Full instructions and guidelines for submitting clinical trials are available Annual Meeting website. Abstracts selected for presentation will be embargoed in accordance with AACR guidelines.
Call for Applications: Computational Genomic Epidemiology of Cancer (CoGEC) Training Program
The Case Comprehensive Cancer Center invites applications to its funded program for research associates, for a start date of August 1, 2015. This program combines a mentored cancer research project designed by the fellow in collaboration with their mentors with a specialized curriculum of formal didactic training and individualized longitudinal curriculum.
This program is designed to prepare research associates for careers as: Independent investigators engaged in research at the intersection of cancer research, genetics, epidemiology, biostatistics, and computer science. Cancer researchers obtaining training will have the skills vital to decipher the complex pathways compromised of genetic and environmental risk factors for disease, and will ultimately be able to provide clinicians and their patients with valuable information for the prevention and treatment of cancer. Salary and research supply funds are highly competitive.
- US citizenship or permanent residency.
- Terminal degree (PhD, MD or MD/PhD).
- Demonstrated skills in quantitative analysis and an interest in a career in cancer genetics research.
For more information about the program and application materials, please visit the Cancer Center website OR contact Lyn Haselton at email@example.com.
Limited Submission: Mary Kay Foundation: Innovative/Translational Cancer Research in Ovarian, Uterine, Breast, or Cervical Cancers
The Mary Kay Foundation™ is currently accepting applications for innovative grants for translational research in ovarian, uterine, breast, or cervical cancer. The program will offer between ten to fifteen grants. The awards will be up to $100,000 each (combined direct and indirect costs). The grant period is for two years. Applications must be submitted by one Principal Investigator, selected by the Institution. Only one grant application will be accepted from each accredited medical school and school of public health in the United States. Grants are limited to the United States. Visit theCancer Center website for application information.
LOI Due to Cancer Center: November 14
Application Due to Sponsor: February 2, 2015
Limited Submission: Damon Runyon Clinical Investigator Award
The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine. The awardee will receive financial support for three years, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to $100,000 of any medical school debt still owed by the awardee. Visit the Cancer Center website for application information.
LOI Due to Cancer Center: November 17
Application Due to Sponsor: February 17, 2015
Limited Submission: NIH Director's Early Independence Award
The NIH Director's Early Independence Awards provide an opportunity for exceptional junior scientists to accelerate their entry into an independent research career by forgoing the traditional post-doctoral training period. Though most newly graduated doctoral-level researchers would benefit by post-doctoral training, a small number of outstanding junior investigators would benefit instead by launching directly into an independent research career. For these select investigators, who have established a record of scientific innovation and research productivity and who have demonstrated unusual leadership, drive, and maturity, post-doctoral training would unnecessarily delay their entry into performing independent research. The NIH Director's Early Independence Awards also provide an opportunity for institutions to invigorate their research programs by bringing in the fresh perspectives of the awardees that they host. Number of Applications Allowed: Two candidates as determined by the institution.
CWRU LOI Deadline: December 1
NIH LOI Deadline: December 30
NIH Application Deadline: January 30, 2015
Doris Duke Charitable Foundation 2015 Clinical Research Mentorships
The Doris Duke Charitable Foundation Announces a new grant competition: 2015 Clinical Research Mentorships. The Clinical Research Mentorship (CRM) program encourages medical students to become physician scientists by partnering them with investigators supported through Doris Duke Medical Research Program grants. Past and present Doris Duke-funded researchers are invited to identify a medical student to mentor for one year and to then apply for this grant as a team. Alternatively, medical students may identify a qualifying Doris Duke researcher and apply together. In either case, the Doris Duke researcher must be the applicant.
CRM grants are available to past and current Doris Duke-supported researchers in the following programs: Clinical Scientist Development Awardees since 1998; Distinguished Clinical Scientist Awardees since 1999; Innovations in Clinical Research Awardees since 2009. Students in good standing at any US medical school working on an MD or DO degree are eligible for this mentorship. Students do not need to be matriculated at the mentor's affiliated medical school.
Deadline: January 13, 2015
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Melanoma Research Alliance Young Investigator Award (including Dermatology Young Investigators), Established Investigator Award (including BMS-MRA Established Investigators), and Pilot Award (including SITC-MRA Pilot Award)
Sidney Kimmel Foundation for Cancer Research Kimmel Translational Science Award
Support of Multi-investigator Initiatives in the Case CCC
NIH BULLETIN – Notices and Funding Opportunities
Notice of Intent to Publish a Funding Opportunity Announcement for Oncology Co-Clinical Imaging Research Resources (U24)(NOT-CA-15-001)
Notice of Change in Next Application Due Date for PAR-14-303 "Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54)"(NOT-GM-14-134)
AHRQ Notice of Intent to Publish a Request for Applications to Disseminate Patient-Centered Outcomes Research (PCOR) through Clinical Decision Support (U19)(NOT-HS-15-002)
The Early Detection Research Network: Biomarker Developmental Laboratories (U01)(RFA-CA-14-014)
The Early Detection Research Network: Clinical Validation Centers (U01)(RFA-CA-14-015)
The Early Detection Research Network: Biomarker Reference Laboratories (U24)(RFA-CA-14-016)
The Early Detection Research Network: Data Management and Coordinating Center (U24)(RFA-CA-14-017)
Environmental Influences during Windows of Susceptibility in Breast Cancer Risk (U01)(RFA-ES-14-012)
Stem Cell-Derived Blood Products for Therapeutic Use (R01)(RFA-HL-15-022)
Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R41)(RFA-HL-15-029)
Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)(RFA-HL-15-030)
Collaborative Activities to Promote Metabolomics Research (Admin Supp)(PA-15-030)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.